Modulation of NF-kappa B, and Bcl-2 in apoptosis induced by cisplatin in HeLa cells

Mutat Res. 1997 Nov 19;381(1):67-75. doi: 10.1016/s0027-5107(97)00150-4.

Abstract

Cisplatin exposure induces apoptosis in HeLa cells. Since the interaction of this drug with DNA produces reactive oxygen species, we performed an analysis of the oxidative stress-responsive factors AP-1 and NF-kappa B. Although AP-1 levels were not modified during cisplatin exposure, electrophoretic mobility shift assays demonstrated an increase in NF-kappa B DNA binding activity that correlated with a decrease of the inhibitory protein I kappa B alpha and a specific relocalization of c-Rel, as assessed by immunoblotting and immunofluorescence. No changes in the levels or localization of p65 were found. Interestingly, I kappa B alpha relocalized to the nucleus, probably in order to regulate the binding of specific complexes. This process was accompanied by a decrease of the antiapoptotic protein Bcl-2, and a relocalization of p53 protein to the nucleus. Since HeLa cells lost most of their p53 protein due to a specific E6-dependent degradation, cisplatin could be inhibiting this degradation, since the p53 total levels were not increased during the exposure to the drug.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Apoptosis* / genetics
  • Blotting, Western
  • Cisplatin / pharmacology*
  • Electrophoresis
  • HeLa Cells
  • Humans
  • NF-kappa B / metabolism*
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / metabolism*
  • Proto-Oncogene Proteins c-rel
  • Transcription Factor AP-1 / metabolism
  • Transcription Factor RelB
  • Transcription Factors*
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • Antineoplastic Agents
  • NF-kappa B
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Proteins c-rel
  • RELB protein, human
  • Transcription Factor AP-1
  • Transcription Factors
  • Tumor Suppressor Protein p53
  • Transcription Factor RelB
  • Cisplatin